Phase II/III trial of BVH 0223 in patients with treatment-resistant affective disorders
Phase of Trial: Phase II/III
Latest Information Update: 01 Nov 2016
At a glance
- Drugs Riluzole (Primary)
- Indications Affective disorders
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- 01 Nov 2016 According to Biohaven Pharmaceutical media release, company plans to initiate Phase 2/3 studies in 4Q2016 and in 2017.
- 27 Apr 2016 According to a Biohaven media release, planned initiation date changed from 1 Feb 2016 to 1 Oct 2016.
- 23 Jul 2015 Data from Phase I trial (see profile 252491) will be used to design this trial, as per a Portage Biotech and Biohaven Pharmaceutical media release.